Expert Analysis
Whatever Happened to Metformin as an Anti-Aging Drug?
Metformin’s longevity promise has met mixed human trial results. We trace the mouse experiments, TAME plans, exercise findings and a new frailty…
Why Do We Age If Our Cells Keep Replacing Themselves?
Cell replacement varies across the body. Long-lived cells, inherited DNA changes and aging tissue help explain why ongoing renewal does not prevent…
FDA Officials Discuss How Longevity Drugs Could Be Evaluated
FDA officials at ARDD discussed possible evidence standards for longevity drugs. The conversation concerns regulatory science, not recognition of aging as a…
Why Can Some Animals Live for Hundreds of Years?
Long-lived species repeatedly invest in DNA maintenance, stress resistance, regeneration and cancer control, but evolution offers no single recipe.
BCG Sees a $350 Billion Gap in Women’s Longevity Care. What Does That Number Mean?
BCG estimates a $350 billion opportunity in women’s midlife longevity care. Its global survey points to unmet demand, while the dollar figure…
The “Guardian Paradox” Proposes a Link Between Chronic DNA Damage Signaling and Aging
A review proposes that DNA damage-response pathways can become chronically overactive with age, connecting cellular senescence, inflammation and stem-cell decline. It is…
Do Biohackers Actually Live Any Longer?
Biohackers measure, supplement and optimize in pursuit of a longer life. The honest answer is that nobody has yet shown they outlive…
Magnitude Biosciences Raises £1.3 Million to Scale Drug Screening in Living Worms
The Durham spinout is expanding VivoScan, an automated whole-worm screening platform. The funding supports scale, but promising worm results still need mammalian…
Moonwalk Raises $70 Million as an Epigenetics Startup Moves Toward the Clinic
Moonwalk Biosciences raised a $70 million Series B to advance adipose-targeted RNAi medicines for obesity and cardiometabolic disease. Its epigenetics-based platform is…
Korsana Closes Cyclerion Merger With $380 Million War Chest for Alzheimer’s Drug Development
Korsana completed its merger with Cyclerion and closed a $380 million financing, giving the Alzheimer’s drug developer approximately $475 million in pro-forma…